Cryo-Cell Intl Inc Financials
Cryo-Cell Intl Inc (CCEL) reported $31.6M in revenue for fiscal year 2025, down 1.3% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Rising gross economics are being absorbed by overhead and payouts, leaving cash generation intact but the balance sheet tight.
FY2025 pushed gross margin up to76.6% while operating margin shrank to1.5% , showing the pressure sits after direct service costs, in overhead and financing, rather than in the core service economics. At the same time, free cash flow remained$5.2M even as net income fell to-$2.4M , because reinvestment needs were unusually light and accounting profit understated near-term cash generation.
The balance sheet is being run with very little cash: year-end cash was
Cash generation is also being pulled in two directions: financing outflows were
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Cryo-Cell Intl Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Cryo-Cell Intl Inc has an operating margin of 1.5%, meaning the company retains $2 of operating profit per $100 of revenue. This below-average margin results in a low score of 22/100, suggesting thin profitability after operating expenses. This is down from 10.9% the prior year.
Cryo-Cell Intl Inc's revenue declined 1.3% year-over-year, from $32.0M to $31.6M. This contraction results in a growth score of 33/100.
Cryo-Cell Intl Inc's current ratio of 0.59 is below the typical benchmark, resulting in a score of 7/100. This tight liquidity could limit financial flexibility if cash inflows slow.
Cryo-Cell Intl Inc converts 16.6% of revenue into free cash flow ($5.2M). This strong cash generation earns a score of 75/100.
Cryo-Cell Intl Inc scores -0.23, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($34.7M) relative to total liabilities ($80.3M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Cryo-Cell Intl Inc passes 6 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
Cryo-Cell Intl Inc reported a net loss of $2.4M while generating $5.5M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.
Cryo-Cell Intl Inc earns $0.23 in operating income for every $1 of interest expense ($482K vs $2.1M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
Cryo-Cell Intl Inc generated $31.6M in revenue in fiscal year 2025. This represents a decrease of 1.3% from the prior year.
Cryo-Cell Intl Inc's EBITDA was $1.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 64.8% from the prior year.
Cryo-Cell Intl Inc reported -$2.4M in net income in fiscal year 2025. This represents a decrease of 704.2% from the prior year.
Cryo-Cell Intl Inc earned -$0.30 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 700.0% from the prior year.
Cash & Balance Sheet
Cryo-Cell Intl Inc generated $5.2M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 45.5% from the prior year.
Cryo-Cell Intl Inc held $319K in cash against $8.4M in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Cryo-Cell Intl Inc's gross margin was 76.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 1.5 percentage points from the prior year.
Cryo-Cell Intl Inc's operating margin was 1.5% in fiscal year 2025, reflecting core business profitability. This is down 9.3 percentage points from the prior year.
Cryo-Cell Intl Inc's net profit margin was -7.7% in fiscal year 2025, showing the share of revenue converted to profit. This is down 9.0 percentage points from the prior year.
Not reported for fiscal year 2025.
Capital Allocation
Cryo-Cell Intl Inc invested $376K in research and development in fiscal year 2025. This represents a decrease of 69.7% from the prior year.
Cryo-Cell Intl Inc spent $170K on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 88.1% from the prior year.
Cryo-Cell Intl Inc invested $230K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 90.4% from the prior year.
CCEL Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $31.1M | $31.6M-1.3% | $32.0M+2.0% | $31.3M+3.3% | $30.3M+5.0% | $28.9M-7.3% | $31.1M-2.1% | $31.8M+8.9% | $29.2M+15.1% | $25.4M+9.8% | $23.1M+9.7% | $21.1M+4.8% | $20.1M+6.0% | $19.0M+5.7% | $18.0M+0.3% | $17.9M |
| Cost of Revenue | $6.9M | $7.4M-7.2% | $7.9M-5.3% | $8.4M-4.6% | $8.8M-2.2% | $9.0M-6.9% | $9.7M-3.8% | $10.0M+17.5% | $8.5M+27.0% | $6.7M | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $24.3M | $24.2M+0.6% | $24.0M+4.7% | $23.0M+6.5% | $21.5M+8.3% | $19.9M-7.4% | $21.5M-1.3% | $21.8M+5.3% | $20.7M+10.8% | $18.7M | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $312K | $376K-69.7% | $1.2M+6.1% | $1.2M+204.4% | $385K+671.6% | $50K+109.1% | $24K-20.9% | $30K-67.2% | $92K+123.1% | $41K-22.5% | $53K+16.0% | $46K-28.9% | $64K+78.0% | $36K-67.0% | $110K-40.4% | $184K |
| SG&A Expenses | $19.0M | $18.2M-1.6% | $18.5M+7.9% | $17.2M+10.2% | $15.6M+6.6% | $14.6M+2.2% | $14.3M-4.0% | $14.9M-4.7% | $15.6M+16.0% | $13.5M-8.4% | $14.7M+18.8% | $12.4M+1.1% | $12.3M+7.8% | $11.4M-21.2% | $14.4M+16.2% | $12.4M |
| Operating Income | -$104K | $482K-86.1% | $3.5M+128.3% | -$12.3M-405.7% | $4.0M+0.2% | $4.0M-47.6% | $7.7M+51.3% | $5.1M-2.4% | $5.2M+3.7% | $5.0M+1054.6% | $434K-85.2% | $2.9M+48.1% | $2.0M+16.4% | $1.7M+199.5% | -$1.7M-518.3% | -$277K |
| Interest Expense | $1.9M | $2.1M+10.8% | $1.9M+50.8% | $1.2M-18.7% | $1.5M+10.4% | $1.4M-10.7% | $1.5M-9.4% | $1.7M+10.1% | $1.5M+18.8% | $1.3M+37.5% | $947K-27.3% | $1.3M+13.2% | $1.2M-17.8% | $1.4M+37.0% | $1.0M-29.8% | $1.5M |
| Income Tax | -$82K | $92K-96.2% | $2.4M+162.5% | -$3.8M-801.8% | $548K+3.8% | $528K-62.7% | $1.4M+28.5% | $1.1M-75.4% | $4.5M+241.8% | $1.3M+212.9% | -$1.2M+83.8% | -$7.2M-5893.8% | $124K-27.2% | $170K-91.0% | $1.9M+998.2% | $172K |
| Net Income | -$2.5M | -$2.4M-704.2% | $402K+104.2% | -$9.5M-443.6% | $2.8M+33.0% | $2.1M-42.5% | $3.6M+58.2% | $2.3M+368.0% | -$855K-136.9% | $2.3M+275.3% | -$1.3M-116.3% | $8.1M+1364.2% | $554K+1917.9% | $27K+100.4% | -$6.3M-201.0% | -$2.1M |
| EPS (Diluted) | — | -$0.30-700.0% | $0.05+104.4% | -$1.14-445.5% | $0.33+32.0% | $0.25-44.4% | $0.45+66.7% | $0.27+345.5% | -$0.11-136.7% | $0.30+287.5% | -$0.16-119.3% | $0.83+1560.0% | $0.05 | $0.00+100.0% | -$0.56-211.1% | -$0.18 |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
CCEL Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $61.7M-4.6% | $64.7M0.0% | $64.7M-0.3% | $64.9M+7.0% | $60.7M+31.3% | $46.2M+7.7% | $42.9M0.0% | $42.9M+79.4% | $23.9M+22.4% | $19.5M+0.2% | $19.5M+91.0% | $10.2M-11.2% | $11.5M-6.7% | $12.3M-36.7% | $19.5M |
| Current Assets | $11.8M-6.3% | $12.6M+32.8% | $9.5M-1.6% | $9.6M-39.1% | $15.8M-14.9% | $18.6M+20.6% | $15.4M+4.3% | $14.8M+15.9% | $12.7M+41.3% | $9.0M-13.0% | $10.4M+21.9% | $8.5M-10.3% | $9.5M+1.6% | $9.3M-33.7% | $14.1M |
| Cash & Equivalents | $319K-43.1% | $561K+38.1% | $406K-76.2% | $1.7M-79.4% | $8.3M-20.2% | $10.4M+58.4% | $6.5M+8.3% | $6.0M-3.8% | $6.3M+79.4% | $3.5M-15.7% | $4.2M+26.6% | $3.3M-16.5% | $3.9M+46.6% | $2.7M-57.5% | $6.3M |
| Inventory | $409K-37.8% | $658K-14.5% | $769K-9.7% | $851K-7.6% | $921K-0.7% | $927K-14.5% | $1.1M-14.0% | $1.3M+300.7% | $315K-12.9% | $361K-24.1% | $476K+646.1% | $64K | N/A | N/A | N/A |
| Accounts Receivable | $6.8M-6.3% | $7.3M+11.1% | $6.6M+8.8% | $6.0M+15.1% | $5.3M-16.9% | $6.3M+3.7% | $6.1M+3.9% | $5.9M+14.5% | $5.1M+26.5% | $4.1M+32.5% | $3.1M-24.9% | $4.1M+22.0% | $3.3M+17.6% | $2.8M-7.3% | $3.1M |
| Goodwill | $1.9M0.0% | $1.9M0.0% | $1.9M0.0% | $1.9M0.0% | $1.9M0.0% | $1.9M0.0% | $1.9M0.0% | $1.9M | $0 | $0-100.0% | $1.8M | $0 | N/A | N/A | N/A |
| Total Liabilities | $80.3M+3.1% | $77.9M+7.8% | $72.3M+8.8% | $66.4M+17.6% | $56.5M+15.6% | $48.9M-2.0% | $49.8M-2.8% | $51.3M+40.9% | $36.4M+4.2% | $35.0M+42.9% | $24.5M+16.8% | $20.9M+0.8% | $20.8M-2.6% | $21.3M-2.7% | $21.9M |
| Current Liabilities | $19.8M-8.4% | $21.6M+3.5% | $20.9M+7.1% | $19.5M-7.6% | $21.1M+28.4% | $16.4M+6.4% | $15.4M0.0% | $15.4M+10.7% | $13.9M+6.3% | $13.1M+25.8% | $10.4M+14.2% | $9.1M-7.0% | $9.8M-8.0% | $10.7M+1.0% | $10.6M |
| Long-Term Debt | $8.4M-1.5% | $8.5M-1.3% | $8.6M-1.5% | $8.7M+360.0% | $1.9M-68.1% | $5.9M-33.7% | $9.0M+528.5% | $1.4M0.0% | $1.4M0.0% | $1.4M-38.0% | $2.3M0.0% | $2.3M0.0% | $2.3M0.0% | $2.3M-19.3% | $2.9M |
| Total Equity | -$18.6M-40.8% | -$13.2M-19.8% | -$11.0M-623.7% | -$1.5M-136.4% | $4.2M+257.0% | -$2.7M+61.7% | -$7.0M+22.0% | -$8.9M+28.8% | -$12.5M+18.9% | -$15.4M-210.5% | -$5.0M+53.7% | -$10.7M-15.7% | -$9.3M-3.0% | -$9.0M-265.7% | -$2.5M |
| Retained Earnings | -$38.4M-17.3% | -$32.8M-5.2% | -$31.2M-44.0% | -$21.6M-29.3% | -$16.7M+11.1% | -$18.8M+16.1% | -$22.4M+11.4% | -$25.3M-3.5% | -$24.5M+8.6% | -$26.8M-5.2% | -$25.5M+24.1% | -$33.6M+0.4% | -$33.7M+0.1% | -$33.8M-23.0% | -$27.4M |
CCEL Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $6.3M | $5.5M-8.9% | $6.0M-32.6% | $8.9M+4.0% | $8.6M+8.2% | $7.9M-6.4% | $8.5M+34.5% | $6.3M+18.0% | $5.3M-6.7% | $5.7M+14.6% | $5.0M+2.8% | $4.9M+212.0% | $1.6M+89.2% | $822K+127.8% | $361K-55.9% | $819K |
| Capital Expenditures | $206K | $230K-90.4% | $2.4M-64.9% | $6.8M-43.8% | $12.2M+563.5% | $1.8M+1734.7% | $100K-84.9% | $662K+48.4% | $446K+353.7% | $98K-71.3% | $343K+216.2% | $108K-10.0% | $121K-65.5% | $350K+161.9% | $134K-73.6% | $506K |
| Free Cash Flow | $6.1M | $5.2M+45.5% | $3.6M+73.4% | $2.1M+157.9% | -$3.6M-159.0% | $6.1M-27.2% | $8.4M+48.5% | $5.6M+15.3% | $4.9M-13.0% | $5.6M+21.0% | $4.6M-2.1% | $4.7M+230.7% | $1.4M+203.8% | $472K+107.7% | $227K-27.5% | $313K |
| Investing Cash Flow | $869K | -$975K+80.0% | -$4.9M+40.1% | -$8.1M+46.7% | -$15.3M-119.8% | -$7.0M-2044.5% | $357K+154.0% | -$662K+94.1% | -$11.3M-12228.4% | $93K | N/A | N/A | N/A | $1.1M+19.4% | $962K+132.5% | -$3.0M |
| Financing Cash Flow | -$6.8M | -$4.7M-384.6% | -$979K+52.8% | -$2.1M-1501.9% | $148K+104.8% | -$3.1M+38.6% | -$5.0M+2.5% | -$5.1M-189.9% | $5.7M+288.3% | -$3.0M | N/A | N/A | N/A | -$724K+85.4% | -$5.0M-6217.1% | $81K |
| Dividends Paid | $0 | $3.2M+59.9% | $2.0M | $0-100.0% | $7.7M | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | $170K-88.1% | $1.4M+78.2% | $799K-56.1% | $1.8M+629.8% | $249K | N/A | $992K | N/A | $447K-95.9% | $10.8M+237.1% | $3.2M+20.0% | $2.7M+261.6% | $739K-56.6% | $1.7M | N/A |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
CCEL Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 76.6%+1.5pp | 75.1%+1.9pp | 73.2%+2.2pp | 71.0%+2.1pp | 68.9%-0.1pp | 69.0%+0.5pp | 68.5%-2.3pp | 70.8%-2.7pp | 73.5% | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | 1.5%-9.3pp | 10.9%+50.1pp | -39.3%-52.5pp | 13.3%-0.6pp | 13.9%-10.7pp | 24.6%+8.7pp | 15.9%-1.9pp | 17.8%-2.0pp | 19.7%+17.8pp | 1.9%-12.0pp | 13.9%+4.1pp | 9.8%+0.9pp | 9.0%+18.5pp | -9.5%-8.0pp | -1.5% |
| Net Margin | -7.7%-9.0pp | 1.3%+31.6pp | -30.4%-39.5pp | 9.1%+1.9pp | 7.2%-4.4pp | 11.6%+4.4pp | 7.2%+10.1pp | -2.9%-12.0pp | 9.1%+14.8pp | -5.7%-44.1pp | 38.4%+35.7pp | 2.8%+2.6pp | 0.1%+35.3pp | -35.1%-23.4pp | -11.7% |
| Return on Equity | N/A | N/A | N/A | N/A | 49.8% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -3.9%-4.6pp | 0.6%+15.3pp | -14.7%-19.0pp | 4.3%+0.8pp | 3.4%-4.4pp | 7.8%+2.5pp | 5.3%+7.3pp | -2.0%-11.7pp | 9.7%+16.4pp | -6.8%-48.3pp | 41.6%+36.2pp | 5.4%+5.2pp | 0.2%+51.4pp | -51.2%-40.4pp | -10.8% |
| Current Ratio | 0.590.0x | 0.58+0.1x | 0.450.0x | 0.49-0.3x | 0.75-0.4x | 1.13+0.1x | 1.000.0x | 0.960.0x | 0.91+0.2x | 0.69-0.3x | 0.99+0.1x | 0.930.0x | 0.96+0.1x | 0.87-0.5x | 1.33 |
| Debt-to-Equity | N/A | N/A | N/A | N/A | 0.45 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Margin | 16.6%+5.4pp | 11.3%+4.6pp | 6.6%+18.5pp | -11.8%-32.9pp | 21.1%-5.8pp | 26.9%+9.2pp | 17.7%+1.0pp | 16.7%-5.4pp | 22.1%+2.1pp | 20.1%-2.4pp | 22.5%+15.4pp | 7.1%+4.6pp | 2.5%+1.2pp | 1.3%-0.5pp | 1.8% |
Note: Shareholder equity is negative (-$18.6M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.59), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Where Cryo-Cell Intl Inc Ranks
Frequently Asked Questions
What is Cryo-Cell Intl Inc's annual revenue?
Cryo-Cell Intl Inc (CCEL) reported $31.6M in total revenue for fiscal year 2025. This represents a -1.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Cryo-Cell Intl Inc's revenue growing?
Cryo-Cell Intl Inc (CCEL) revenue declined by 1.3% year-over-year, from $32.0M to $31.6M in fiscal year 2025.
Is Cryo-Cell Intl Inc profitable?
No, Cryo-Cell Intl Inc (CCEL) reported a net income of -$2.4M in fiscal year 2025, with a net profit margin of -7.7%.
What is Cryo-Cell Intl Inc's EBITDA?
Cryo-Cell Intl Inc (CCEL) had EBITDA of $1.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Cryo-Cell Intl Inc have?
As of fiscal year 2025, Cryo-Cell Intl Inc (CCEL) had $319K in cash and equivalents against $8.4M in long-term debt.
What is Cryo-Cell Intl Inc's gross margin?
Cryo-Cell Intl Inc (CCEL) had a gross margin of 76.6% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Cryo-Cell Intl Inc's operating margin?
Cryo-Cell Intl Inc (CCEL) had an operating margin of 1.5% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Cryo-Cell Intl Inc's net profit margin?
Cryo-Cell Intl Inc (CCEL) had a net profit margin of -7.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Cryo-Cell Intl Inc's free cash flow?
Cryo-Cell Intl Inc (CCEL) generated $5.2M in free cash flow during fiscal year 2025. This represents a 45.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Cryo-Cell Intl Inc's operating cash flow?
Cryo-Cell Intl Inc (CCEL) generated $5.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Cryo-Cell Intl Inc's total assets?
Cryo-Cell Intl Inc (CCEL) had $61.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Cryo-Cell Intl Inc's capital expenditures?
Cryo-Cell Intl Inc (CCEL) invested $230K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Cryo-Cell Intl Inc spend on research and development?
Cryo-Cell Intl Inc (CCEL) invested $376K in research and development during fiscal year 2025.
What is Cryo-Cell Intl Inc's current ratio?
Cryo-Cell Intl Inc (CCEL) had a current ratio of 0.59 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Cryo-Cell Intl Inc's return on assets (ROA)?
Cryo-Cell Intl Inc (CCEL) had a return on assets of -3.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Why is Cryo-Cell Intl Inc's debt-to-equity ratio negative or not reported?
Cryo-Cell Intl Inc (CCEL) has negative shareholder equity of -$18.6M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Cryo-Cell Intl Inc's Altman Z-Score?
Cryo-Cell Intl Inc (CCEL) has an Altman Z-Score of -0.23, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Cryo-Cell Intl Inc's Piotroski F-Score?
Cryo-Cell Intl Inc (CCEL) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Cryo-Cell Intl Inc's earnings high quality?
Cryo-Cell Intl Inc (CCEL) reported a net loss of $2.4M while generating $5.5M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Cryo-Cell Intl Inc cover its interest payments?
Cryo-Cell Intl Inc (CCEL) has an interest coverage ratio of 0.23x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Cryo-Cell Intl Inc?
Cryo-Cell Intl Inc (CCEL) scores 28 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.